News › GlobeNewswire Inc.

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

GlobeNewswire Inc. • Jan 14, 2026 7:00am (New York) •By C4 Therapeutics, Inc.

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

C4 Therapeutics announced strategic milestones through 2028 for advancing cemsidomide, an investigational IKZF1/3 degrader for multiple myeloma. The company plans to initiate Phase 2 MOMENTUM trial in Q1 2026 and Phase 1b combination trial with elranatamab in Q2 2026, with a recommended Phase 2 dose of 100 µg. Phase 1 data showed 53% overall response rate at the highest dose. The company also outlined a new discovery strategy targeting inflammation and neurodegenerative diseases, with cash runway extending through end of 2028.

← Back to news Read Original Article

Insights

SIEGY neutral

Listed as a market player with energy storage systems

CCCC positive

Company demonstrated strong Phase 1 efficacy data (53% ORR at 100 µg dose), secured regulatory pathway for potential dual accelerated approvals, initiated two new clinical trials, expanded discovery pipeline with novel targets, and extended cash runway to end of 2028. Multiple value inflection points planned through 2028 support positive momentum.

Keywords

#cemsidomide #IKZF1/3 degrader #multiple myeloma #Phase 2 MOMENTUM trial #elranatamab #targeted protein degradation #clinical development #BiTE therapy #drug development

Tickers

CCCC MKKGY RHHBY BIIB

← Prev: TotalEnergies Strengthens Portfolio With Bahrain JV, Nigeria Sale

Next: Rail Vision Successfully Completes Strategic Acquisition of Majority Stake in Cutting-Edge Quantum Computing Company for Transportation →